Novartis has finally given up on iscalimab after deciding that the anti-CD40 antibody is not worth pursuing in Sjögren’s syndrome. On a fourth-quarter earnings call with the media this morning, ...

VIENNA — Nipocalimab, iscalimab, and tibulizumab, but not lusvertikimab, appear to be promising new agents for Sjögren disease that warrant further investigation, suggest the results of four separate ...

Novartis is pulling back the curtain on late-stage Sjögren’s wins, revealing an edge for its investigational monoclonal antibody ianalumab over placebo in both studies. “Clearly, with Sjögren's having ...

Tibulizumab (ZB-106) was well tolerated and neutralized IL-17A and BAFF in a Phase 1 study in patients with Sjogren’s syndrome Preclinical data demonstrating the potential of dual inhibition of IL-17A ...

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its ...